Canada Markets closed

Revive Therapeutics Ltd. (RVVTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3300+0.0100 (+3.13%)
At close: 03:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.3200
Open0.3257
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3100 - 0.3510
52 Week Range0.1200 - 0.4830
Volume415,235
Avg. Volume443,496
Market Cap105.091M
Beta (5Y Monthly)-0.36
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

    TORONTO, July 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and

  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector Boston Beer announced the launch of a new line of cannabis-infused iced teas. Decibel reported rising revenue in Q1. Ayr Wellness reported positive revenue of $111.2 million, up 90% YoY. Key Takeaways; Psychedelic Sector Awakn filed PCT application for the treatment of behavioral addictions. The FDA gave Revive Therapeutics positive feedback […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.

  • GlobeNewswire

    Revive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation

    WHO reports 650 probable cases of acute hepatitis of unknown aetiology in children from 33 countries Company received FDA orphan drug designation for Bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation and Cannabidiol for autoimmune hepatitis Company intends to move its head office to the US to better support growing drug programs with Bucillamine, Cannabidiol, and Psilocybin TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the